Neutralization of inhibitory pathways in lymphocytes

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10711063
APP PUB NO 20170291947A1
SERIAL NO

15511778

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
INNATE PHARMAMARSEILLE FRANCE MARSEILLE BOUCHES-DU-RHONE

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Andre, Pascale Marseilles, FR 31 339
Blery, Mathieu Marseilles, FR 25 157
Paturel, Carine Marcy l'Etoile, FR 52 237
Wagtmann, Nicolai Cassis, FR 33 179

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 14, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 14, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00